🔎 Trials Near Me

መነሻ › ኖን-ስማል ሴል የሳንባ ካንሰር › ሚዙሪ › Kansas City

በKansas City፣ MO ለኖን-ስማል ሴል የሳንባ ካንሰር የሚደረጉ ክሊኒካዊ ጥናቶች

ለኖን-ስማል ሴል የሳንባ ካንሰር የሚደረጉ 31 ጥናቶች በKansas City እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።

Official study text (English)

ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • St. Lukes Hosp. of Kansas City /ID# 259940, Kansas City
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦክቶ 2026 · NCT04928846

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Truman Medical Center ( Site 0126), Kansas City
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦክቶ 2026 · NCT06345729

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Saint Luke's Hospital of Kansas City, Kansas City
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦክቶ 2026 · NCT04267848

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • University Health Truman Medical Center, Kansas City
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06498635

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • St. Lukes Hospital of Kansas City, Kansas City
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06625775

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • The University of Kansas Cancer Center, Westwood · 5 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT06881784

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • University of Kansas Cancer Center, Westwood · 5 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05498428

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Truman Medical Ctr West, Kansas City
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06667076

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Research Site, Westwood · 5 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06218914

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Saint Luke's Hospital of Kansas City, Kansas City
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06758401

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Research Site, Kansas City
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT06357533

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Local Institution - 0498, Kansas City
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT06561386

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Research Site, Kansas City
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሴፕቴ 2026 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Clinical Study Site, Kansas City
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሴፕቴ 2026 · NCT06767514

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • University of Kansas, Westwood · 5 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT07020117

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

ተሳታዮችን በመፈለግ ላይደረጃ 2/3
  • University of Kansas Medical Center /ID# 263196, Westwood · 5 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT06236438

A Phase 1/1b Study of IAM1363 in HER2 Cancers

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Saint Luke's Cancer Institute, Kansas City
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT06253871

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • The University of Kansas Cancer Center - Westwood, Westwood · 5 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT06119581

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • University of Kansas Cancer Center - North, Kansas City
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ኦገስ 2026 · NCT06500481

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • University of Kansas Medical Center (KUMC), Westwood · 5 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ኦገስ 2026 · NCT05579366

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MidAmerica Cancer Care, Kansas City
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ጁላይ 2026 · NCT06131840

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The University of Kansas Cancer Center - Westwood, Westwood · 5 ማይል ርቀት
  • University of Kansas Cancer Center, Westwood · 5 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT04389632

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • University of Kansas Cancer Center - North, Kansas City
  • University of Kansas Cancer Center, Westwood · 5 ማይል ርቀት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ጁን 2026 · NCT06216301

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • The University of Kansas Cancer Center, Westwood · 5 ማይል ርቀት
እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ11 ጁን 2026 · NCT05361174

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • University Health Truman Medical Center, Kansas City
  • University of Kansas Cancer Center - Briarcliff, Kansas City
  • University of Kansas Cancer Center - North, Kansas City
  • እና 1 ተጨማሪ
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ጁን 2026 · NCT05642572

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Research Site, Kansas City
እድሜ ከ18 እስከ 130 · ሁሉም ጾታዎች · የተሻሻለው በ14 ሜይ 2026 · NCT06417814

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • University Health Truman Medical Center, Kansas City
  • University of Kansas Cancer Center - Briarcliff, Kansas City
  • University of Kansas Cancer Center - North, Kansas City
  • እና 1 ተጨማሪ
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ6 ሜይ 2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2/3
  • University Health Truman Medical Center, Kansas City
  • University of Kansas Cancer Center - Briarcliff, Kansas City
  • Kansas City Veterans Affairs Medical Center, Kansas City
  • እና 2 ተጨማሪ
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ሜይ 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • University Health Truman Medical Center, Kansas City
  • University of Kansas Cancer Center - Briarcliff, Kansas City
  • University of Kansas Cancer Center - North, Kansas City
  • እና 1 ተጨማሪ
18 Minutes · ሁሉም ጾታዎች · የተሻሻለው በ5 ሜይ 2026 · NCT06031688

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • University Health Truman Medical Center, Kansas City
  • University of Kansas Cancer Center - Briarcliff, Kansas City
  • University of Kansas Cancer Center - North, Kansas City
  • እና 1 ተጨማሪ
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ማርች 2026 · NCT06418204

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • Massive Bio SYNERGY-AI site, Kansas City
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦክቶ 2025 · NCT03452774

በሌሎች ከተሞች ለኖን-ስማል ሴል የሳንባ ካንሰር የሚደረጉ ጥናቶች

በKansas City ውስጥ ያሉ ሌሎች ጥናቶች

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።